Navigation Links
Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference
Date:11/24/2009

SAN DIEGO, Nov. 24 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use diagnostic system for measuring an individual's response to multiple antiplatelet agents (e.g. Plavix® and aspirin), announced today that Timothy I. Still, President and CEO of Accumetrics, and Gregory J. Tibbitts, Chief Financial Officer of Accumetrics, will be presenting a corporate overview at the 21st Annual Piper Jaffray Health Care Conference being held in New York City on December 1-2, 2009 at The Palace Hotel.

This presentation comes on the heels of Accumetrics' VerifyNow P2Y12 Test being one of multiple methods recently evaluated during a Late Breaking Clinical Trials session at the American Heart Association Scientific Sessions 2009.

Accumetrics' presentation will be on Tuesday, December 1, 2009 at 9:10 am eastern time. Management will also be available for one-on-one meetings with investors participating in Piper Jaffray's Health Care Conference. For those who would like to schedule an appointment with Accumetrics' management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at afields@lhai.com or contact your Piper Jaffray representative.

About Accumetrics

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform to help physicians determine an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient(TM)) and clopidogrel (Plavix)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions. For more information about the Company and its products, visit www.accumetrics.com.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis. Effient is a trademark of Eli Lilly and Company.


CONTACT:
Megan Rusnack
Lippert/Heilshorn & Associates
212-838-3777
mrusnack@lhai.com

Timothy I. Still
President and CEO
Accumetrics
858-404-8260
press@accumetrics.com

SOURCE Accumetrics, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Accumetrics Announces $16.5M in New Capital Financing
2. Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled
3. Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial
4. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
5. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
6. Echo Therapeutics to Present at the New York Society of Security Analysts 13th Annual Biotech and Specialty Pharmaceuticals Conference
7. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
8. Zimmer Holdings to Present at 21st Annual Piper Jaffray Health Care Conference
9. Isis Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
10. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):